 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Hugel posted its best-ever performance in the second quarter.
Hugel announced on the 9th that its consolidated sales rose 27.7% year-on-year to 81.6 billion won in the second quarter of this year. Operating profit during the same period also reached 28 billion won, up 27.5 percent from the same period last year. This is the highest performance ever in the second quarter.
The reason for the second-quarter earnings record was the increase in domestic and overseas sales of botulinum toxin formulation Botulax. Botulinx sales in the second quarter increased 17% year-on-year.
In Korea, the distribution channel has been expanded to online to solidify its leading position, while overseas, it has been solid in Asian markets such as Japan, Thailand and Taiwan. In April, it officially launched Botulinx in Australia and completed its entry into 23 European countries.
Sales of HA fillers have also increased significantly. HA filler sales in the second quarter increased 43% year-on-year.
Domestic sales surged 103% from the second quarter of last year on the back of increased advertising for consumers and strengthened academic promotions. Sales have also continued to rise in the Asia-Pacific region and major European countries such as France, Poland, Germany and the United Kingdom.
Derma Cosmetics brand sales increased 41% year-on-year. This is due to the addition of new online distribution marketing channels in addition to existing H&B stores and home shopping. Lifting room Blue Rose also achieved 20% growth by expanding its lineup.
Hugel plans to expand its domestic market share with differentiated sales and marketing in the second half of the year.
In Australia, it is expected to achieve a 5% share of the botulinum toxin market this year based on local networks built through the supply of HA fillers. In Europe, it plans to continue to increase the number of countries that supply both Botulax and HA fillers.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
